Progressive Supranuclear Palsy Market By Drugs Pipeline Stage 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Progressive Supranuclear Palsy Market
Progressive Supranuclear Palsy Market: By Drugs Pipeline Stage (Early Stage, Clinical Trial, Late Stage and Others) & By Geography (Asia-Pacific, North America, Europe and RoW) - Forecast (2016-2021)
Report Code : HCR 0269
Updated Date: 23 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Palsy is defined as class of neuro-degenerative disorders seen amongst many people across the world. Palsy is frequently seen among the geriatric population, palsy is not necessarily endemic to older generation or a specific race, infact they have also been reported in much younger populations, although the reason may be different (trauma/abuse). Progressive supranuclear palsy, sometimes also called Steele-Richardson-Olszewski syndrome, is an uncommon brain disorder that causes serious problems with walking, balance and eye movements. The disorder results from deterioration of cells in areas of your brain that control body movement and thinking. Progessive supranuclear palsy is diagnosed by loss of balance while walking, inability to aim your eyes properly and several other symptoms like Stiffness and awkward movements, Falling, Problems with speech & swallowing and Sensitivity to light. However, higher cost of the treatments and R&D costs involved into developing new drugs and therapies is expected to be key restraint for the growth of the amyloids market over a period of study.

This report identifies the global progressive supranuclear palsy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to progressive supranuclear palsy market.
Progressive Supranuclear Palsy Market

Geographically, North America dominated the progressive supranuclear palsy market due to because of high awareness, higher spending on healthcare compared to other economies and appropriate reimbursement circumstances and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as the second and third largest consumer of progressive supranuclear palsy. Asia Pacific is projected to have the fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.

This report segments progressive supranuclear palsy market on the basis of drug pipeline state and regional market as follows:
  • On the basis of drug pipeline stage this report on progressive supranuclear palsy market is segmented as follows, covering major segments type as follows: Early Stage, Clinical Trial, Late Stage and others
  • This report on progressive supranuclear palsy has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the progressive supranuclear palsy market. Some of the major companies’ profiles in detail are as follows:
  • Merck & Co
  • Aton Pharmaceuticals Inc.
  • Bristol Myers Squibb Co.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.,
1. Progressive Supranuclear Palsy Market – Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Progressive Supranuclear Palsy Market–Forces
   4.1. Drivers
      4.1.1. Growing awareness about progressive supranuclear palsy amongst people
      4.1.2. Increasing investment by companies in R&D
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Progressive Supranuclear Palsy Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life cycle Analysis
   5.5. Suppliers & Distributors
6. Progressive Supranuclear Palsy Market, By Drug Pipeline Stage
   6.1. Early Stage
   6.2. Clinical Trial
   6.3. Late Stage
   6.4. Others
7. Progressive Supranuclear Palsy Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Progressive Supranuclear Palsy – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Merck & Co
   9.2. Aton Pharmaceuticals Inc.
   9.3. Bristol Myers Squibb Co.
   9.4. GlaxoSmithKline PLC
   9.5. Novartis AG
   9.6. Teva Pharmaceutical Industries Ltd.,
   9.7. AB Science SA
   9.8. AbbVie Inc.
   9.9. AlzProtect SAS
   9.10. Cortice Biosciences, Inc.
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibiliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports